A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393–1414.
   PubMed Web of Science ®Google Scholar
• Mlynek A, Magerl M, Hanna M, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009;64:927–936.
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:67–75.
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924–935.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101–109.
   PubMed Web of Science ®Google Scholar
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742–1750 e4.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther 2013;13:1225–1228.
   PubMed Web of Science ®Google Scholar
• MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008–2018. Expert Rev Clin Immunol 2019;15:553–569.
   PubMed Web of Science ®Google Scholar
• Mansur AH, Srivastava S, Mitchell V, et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med 2017;124:36–43.
   PubMed Web of Science ®Google Scholar
• Maurer M, Kaplan A, Rosen K, et al. The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 2018;141:1138–1139 e7.
   PubMed Web of Science ®Google Scholar
• Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004;59:869–873.
   PubMed Web of Science ®Google Scholar
• Turk M, Kocaturk E, Cure K, Yilmaz I. Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. J Allergy Clin Immunol Pract 2018;6:1389–1390.
   PubMed Web of Science ®Google Scholar
• Kocaturk E, Deza G, Kiziltac K, Gimenez-Arnau AM. Omalizumab updosing for better disease control in chronic spontaneous urticaria patients. Int Arch Allergy Immunol 2018;177:360–364.
   PubMed Web of Science ®Google Scholar
• Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2013;110:113–117.
   PubMed Web of Science ®Google Scholar
• Maurer M, Metz M, Bindslev-Jensen C, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy 2016;71:1210–1218.
   PubMed Web of Science ®Google Scholar
• Maurer M, Mathias SD, Crosby RD, et al. Validity and responsiveness of the Urticaria Activity and Impact Measure: a new patient-reported tool. Ann Allergy Asthma Immunol 2018;120:641–647.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014;133:1365–72. 72 e1–6.
   PubMed Web of Science ®Google Scholar
• Kocaturk E, Kiziltac U, Can P, et al. Validation of the Turkish version of the Urticaria Control Test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria. World Allergy Organ J 2019;12:100009.
   PubMed Web of Science ®Google Scholar
• Silva PM, Costa AC, Mendes A, Barbosa MP. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr) 2015;43:168–173.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014;150:288–290.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014;73:57–62.
   PubMed Web of Science ®Google Scholar
• Mandel VD, Guanti MB, Liberati S, et al. Omalizumab in chronic spontaneous urticaria refractory to conventional therapy: an Italian retrospective clinical analysis with suggestions for long-term maintenance strategies. Dermatol Ther (Heidelb) 2018;8:291–301.
   PubMed Web of Science ®Google Scholar
• Buyukozturk S, Gelincik A, Demirturk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 2012;39:439–442.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol 2016;137:474–481.
   PubMed Web of Science ®Google Scholar
• Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139:1059–1061 e1.
   PubMed Web of Science ®Google Scholar
• Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response. Ann Allergy Asthma Immunol 2018;121:474–478.
   PubMed Web of Science ®Google Scholar
• Turk M, Yilmaz I, Nazik Bahcecioglu S, et al. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment. Dermatol Ther 2021;(34(1):e14543.
   PubMed Web of Science ®Google Scholar
• Clark JJ, Secrest AM, Hull CM, et al. The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: retrospective chart review. J Am Acad Dermatol 2016;74:1274–1276.
   PubMed Web of Science ®Google Scholar
• Lefevre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol 2013;25:242–245.
   PubMed Web of Science ®Google Scholar
• Sussman G, Hebert J, Gulliver W, et al. Omalizumab retreatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial. J Allergy Clin Immunol Pract 2020;8(7):2372–2378.e5.
   PubMed Web of Science ®Google Scholar
• Kavati A, Zhdanava M, Ortiz B, et al. Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. Allergy Asthma Proc 2019;40:321–328.
   PubMed Web of Science ®Google Scholar
• Ensina LF, de Lacerda AE, Machado LM, et al. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience. Ann Allergy Asthma Immunol 2015;115:536.
   PubMed Web of Science ®Google Scholar
• Pinto Gouveia M, Gameiro A, Pinho A, Goncalo M. Long-term management of chronic spontaneous urticaria with omalizumab. Clin Exp Dermatol 2017;42:735–742.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence. Expert Opin Biol Ther 2018;18:425–448.
   PubMed Web of Science ®Google Scholar
• Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice. Drug Des Devel Ther 2019;13:3181–3186.
   PubMed Web of Science ®Google Scholar